The patient undergoes an initial assessment to confirm eligibility for the study. This includes verifying a diagnosis of Waldenstrom Macroglobulinemia (WM) and ensuring the patient has received at least two prior lines of therapy.

The patient’s performance status is evaluated using the Eastern Cooperative Oncology Group (ECOG) scale, which ranges from 0 (fully active) to 2 (capable of self-care but unable to carry out any work activities).

The patient begins treatment with CLR 131, administered through an intravenous infusion. The specific dosage and frequency are determined by the study protocol.

In addition to CLR 131, the patient may receive potassium iodide orally as a supportive medication.

The patient is monitored for response to treatment and any side effects. This includes regular assessments of vital signs, laboratory tests, and electrocardiograms (ECGs).

The patient’s response to treatment is evaluated using criteria modified from the VIth Waldenstrom’s Macroglobulinemia Criteria for Response Assessment.

The patient undergoes follow-up assessments to determine the duration of response and overall response rate. These assessments continue for up to 12 months after the first infusion of CLR 131.

The study also evaluates treatment-free survival, which is the time from the last CLR 131 dose to the initiation of subsequent therapy or death.

Throughout the study, the patient is monitored for safety, including any adverse events or serious adverse events. The severity of these events is graded, and the patient’s ECOG performance status is regularly assessed.